2-((6-bromopyridin-2-yl)(methyl)amino)ethan-1-ol | 955369-65-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-((6-bromopyridin-2-yl)(methyl)amino)ethan-1-ol
• 英文别名: 2-[(6-bromopyridin-2-yl)(methyl)amino]ethanol；2-((6-Bromopyridin-2-yl)(methyl)amino)ethanol；2-[(6-bromopyridin-2-yl)-methylamino]ethanol
• CAS: 955369-65-0
• 化学式: C₈H₁₁BrN₂O
• 分子量: 231.092
• InChiKey: ZZRXJDOKERFARS-UHFFFAOYSA-N

物化性质

• 沸点：
  369.3±32.0 °C(Predicted)
• 密度：
  1.531±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-甲基-2-羟基乙胺 、 2-溴-6-氟吡啶 在 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 5.0h， 以86%的产率得到2-((6-bromopyridin-2-yl)(methyl)amino)ethan-1-ol
  参考文献：
  名称：

  [EN] C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME
  [FR] COMPOSÉ INHIBITEUR DE TYROSINE KINASE C-ABL, MODES DE RÉALISATION, PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS

  摘要：

  本文披露了一种抑制c-Abl酪氨酸激酶（本文中也称为"c-Abl"）的化合物实施例。本文描述的这些化合物实施例是新颖的c-Abl抑制剂，可以结合到c-Abl的一个变构位点，并在各种途径中抑制其活性。这些化合物实施例还能够穿过血脑屏障，因此在抑制影响大脑途径和/或蛋白质的c-Abl活性方面是有用的。本文描述的这些化合物实施例是治疗涉及c-Abl的疾病的有效治疗剂，如癌症、运动神经元疾病和神经退行性疾病。本文还披露了制备和使用c-Abl抑制化合物实施例的方法实施例。

  公开号：

  WO2019173761A1

文献信息

• Dihydropyrazolopyrimidinone derivatives
  申请人：Sagara Takeshi

  公开号：US20070254892A1

  公开（公告）日：2007-11-01

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  该发明涉及一般式（I）的化合物，其中Ar1是可选择取代的芳基或杂环芳基；R1是可选择取代的较低烷基、较低烯烃基、较低炔烃基或环状较低烷基基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R2是氢原子、较低烷基基团、较低烯烃基团或较低炔烃基团，或是具有取代基的芳基、芳基烷基或杂环芳基；R3是氢原子或较低烷基基团；R4是氢原子、卤素原子、羟基、较低烷基基团或—N(R1k)R1m基团；T和U是氮原子或亚甲基基团等。该发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域中特别适用于治疗各种癌症。
• DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES
  申请人：Sagara Takeshi

  公开号：US20110189130A1

  公开（公告）日：2011-08-04

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及一般式(I)的化合物：其中Ar1是可选取代的芳基或杂环芳基基团；R1是可选取代的低碳基、低烯基、低炔基或环-低碳基基团，或是带有取代基的芳基、芳基烷基或杂环芳基基团；R2是氢原子、低碳基、低烯基或低炔基，或是带有取代基的芳基、芳基烷基或杂环芳基基团；R3是氢原子或低碳基；R4是氢原子、卤素原子、羟基、低碳基或—N(R1k)R1m基团；T和U是氮原子或甲基基团等。该发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域，特别是治疗各种癌症方面非常有用。
• Dihydropyrazolopyrimidinone Derivatives
  申请人：Sakamoto Toshihiro

  公开号：US20100063024A1

  公开（公告）日：2010-03-11

  The invention relates to compounds of a general formula (I): wherein Ar 1 is an optionally-substituted aryl or heteroaromatic group; R 1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R 3 is a hydrogen atom or a lower alkyl group; R 4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R 1k )R 1m ; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及一般式（I）的化合物：其中Ar1是可选取取代基的芳基或杂环芳基基团；R1是可选取取代基的低碳基、低烯基、低炔基或环低碳基基团，或是带取代基的芳基、芳基烷基或杂环芳基基团；R2是氢原子、低碳基、低烯基或低炔基，或是带取代基的芳基、芳基烷基或杂环芳基基团；R3是氢原子或低碳基；R4是氢原子、卤素原子、羟基、低碳基或-N（R1k）R1m基团；T和U是氮原子或甲基烷基等。本发明的化合物具有出色的Weel激酶抑制作用，因此在药物领域中特别适用于治疗各种癌症。
• Substituted pyrazolo[3,4-d]pyrimidinone derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07834019B2

  公开（公告）日：2010-11-16

  The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及一般式（I）的化合物：其中Ar1是可选取代的芳基或杂芳基基团；R1是可选取代的低烷基、低烯基、低炔基或环低烷基基团，或是一个芳基、芳基烷基或可选带有取代基的杂芳基基团；R2是氢原子、低烷基、低烯基或低炔基，或是一个芳基、芳基烷基或可选带有取代基的杂芳基基团；R3是氢原子或低烷基；R4是氢原子、卤素原子、羟基、低烷基或—N（R1k）R1m的基团；T和U是氮原子或甲基基团等。本发明的化合物具有优异的Weel激酶抑制作用，因此在药物领域，特别是治疗各种癌症方面具有用途。
• DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP2017278A1

  公开（公告）日：2009-01-21

  The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of -N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.

  本发明涉及通式 (I) 的化合物： 其中 Ar1 是任选取代的芳基或杂芳基；R1 是任选取代的低级烷基、低级烯基、低级炔基或环低级烷基，或者是任选具有取代基的芳基、芳烷基或杂芳基；R2 是氢原子、低级烷基、低级烯基或低级炔基，或任选具有取代基的芳基、芳烷基或杂芳基； R3 是氢原子或低级烷基； R4 是氢原子、卤素原子、羟基、低级烷基或-N(R1k)R1m 的基团； T 和 U 是氮原子或甲基等。 本发明的化合物具有优异的韦氏激酶抑制作用，因此在医药领域，特别是治疗各种癌症方面非常有用。